Hugh Davis, PhD
Pre-clinical Development & Biologics Advisor
Dr. Hugh M. Davis joined the Empire Discovery Institute’s Scientific Advisory Board in August 2019. He has over 30 years of experience in the pharmaceutical, biotechnology and CRO industries. In addition to serving on the EDI SAB Hugh is currently Chief Business Officer at Frontage Laboratories where he helped take the company public on the Hong Kong Exchange in May 2019. Prior to joining Frontage, Hugh served as Vice President and Head of Biologics Development Sciences at Centocor/Janssen R&D of Johnson & Johnson where he and his team were instrumental in the development and approval of many biologic therapies including Remicade®, Stelara®, Simponi®, Sylvant®, Darzalex® and Tremfya®. Prior to J&J, Hugh led the Pharmacodynamics & Exploratory Research Laboratory in the Clinical Pharmacology Unit at Glaxo SmithKline from 1996 to 2001. Hugh has over 75 manuscripts, book chapters and invited review articles in refereed journals.
Following receipt of his Bachelor’s degree in Chemistry from Gannon University in 1980 and Master’s and Doctorate degrees in Biochemistry under Dr. John Edwards from Villanova University in 1983 and 1985, Hugh then completed a Post-Doctoral Fellowship at Centocor, Inc. where he patented the characterization of the CA 125 cancer antigen, a marker used in the diagnosis of ovarian cancer. Hugh has taught Chemistry, Biochemistry and Physics at a number of universities including Thomas Jefferson and Villanova Universities. Hugh is a member of the Villanova University College of Liberal Arts and Sciences Dean’s Advisory Council.
